Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study

By afschroeder • June 21, 2025

Maertens JA, Thompson GR 3rd, Spec A, Donovan FM, Hammond SP, Bruns AHW, Rahav G, Shoham S, Johnson R, Rijnders B, Schaenman J, Hoenigl M, Morrissey CO, Mehta SR, Heath CH, Koehler P, Paterson DL, Slavin MA, Fortún J, Nguyen MH, Patterson TF, Uspenskaya O, Van de Veerdonk FL, Verweij PE, Aoun M, Georgala A, Alexander BD, Chayakulkeeree M, Mehra V, Miceli MH, Sikka MK, Solé A, Walsh TJ, Aguado JM, Holland SM, Moussa M, Rautemaa-Richardson R, Bazaz R, Schwartz S, Walsh SR, Plate M, Yehudai-Ofir D, Brüggemann RJ, Cornely OA, Ostrosky-Zeichner L, Vazquez JA, White PL, Cornelissen K, Ross GG, Fitton L, Dane A, Zinzi D, Rex JH, Chen SC. Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study. Lancet Infect Dis. 2025 Jun 17:S1473-3099(25)00224-5. doi: 10.1016/S1473-3099(25)00224-5. Epub ahead of print. PMID: 40541222.

Tags: Infectious Diseases, Kern, Publications

Intersecting Vulnerabilities: Depression, Suicidality, and HIV Risk Among Young Mothers in South Africa

Miller AP, Joseph Davey DL, Groenewald C, Filiatreau LM, Petersen Z, van Rooyen H, Essack Z. Intersecting Vulnerabilities: Depression, Suicidality, and HIV Risk Among Young[...]

Atomically Precise Polyanionic Boron Cluster Agents with Broad-Spectrum Antiviral Activity

Wang Y, Arumugam B, Doud E, DeLuca D, Rebelo M, Yang OO, Spokoyny AM. Atomically Precise Polyanionic Boron Cluster Agents with Broad-Spectrum Antiviral Activity. Precis[...]

Don’t Drop the B: Risk of Hepatitis B Virus Infection and Reactivation in the Era of Tenofovir-Sparing Regimens for Treatment and Prevention of HIV

Lee TH, Bhattacharya D, Kim HN. Don't Drop the B: Risk of Hepatitis B Virus Infection and Reactivation in the Era of Tenofovir-Sparing Regimens for[...]